These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 3227498)
21. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk. Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527 [No Abstract] [Full Text] [Related]
22. The US drug safety system: role of the pharmaceutical industry. Gibson BR; Suh R; Tilson H Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741 [TBL] [Abstract][Full Text] [Related]
23. Reporting drug product defects--JCAHO. Hoffmann RP Hosp Pharm; 1989 Feb; 24(2):143-4. PubMed ID: 10318199 [No Abstract] [Full Text] [Related]
24. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Bégaud B; Evreux JC; Jouglard J; Lagier G Therapie; 1985; 40(2):111-8. PubMed ID: 4002188 [No Abstract] [Full Text] [Related]
25. Issues with regulatory pharmacovigilance in East European countries: the industry perspective. Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561 [TBL] [Abstract][Full Text] [Related]
26. [Drug surveillance as seen by the general practitioner. Apropos of a survey of 4175 physicians]. Begaud B; Haramburu F; Péré JC; Delmas N; Lorson B; Albin H Therapie; 1984; 39(5):453-7. PubMed ID: 6506000 [No Abstract] [Full Text] [Related]
27. [Cost/benefit analysis of a regional drug surveillance center]. Mignot G; Chichmanian RM; Spreux A; Bernard G Therapie; 1988; 43(5):377-8. PubMed ID: 3147546 [No Abstract] [Full Text] [Related]
28. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. Coplan PM; Noel RA; Levitan BS; Ferguson J; Mussen F Clin Pharmacol Ther; 2011 Feb; 89(2):312-5. PubMed ID: 21160469 [No Abstract] [Full Text] [Related]
29. Issues in bringing new drugs to the market. Ansbacher R Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16322437 [No Abstract] [Full Text] [Related]
32. Statewide test of a new postmarketing drug surveillance system. Fisher S; Bryant SG; Solovitz BL; Kluge RM Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262 [No Abstract] [Full Text] [Related]
33. Issues in bringing new drugs to the market. Ammann AJ Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329171 [No Abstract] [Full Text] [Related]
34. Current status of the drug safety monitoring system in Korea. Park BJ Pharmacoepidemiol Drug Saf; 2001; 10(6):557-60. PubMed ID: 11828840 [No Abstract] [Full Text] [Related]
35. [Advantages of a microcomputer system in researching duplicated reports]. Biour M; Wagniart F; Jablonka J; Hamel JD; Weissenburger J; Cheymol G Therapie; 1986; 41(5):383-4. PubMed ID: 3810530 [No Abstract] [Full Text] [Related]
37. Measuring adverse drug reactions in a postmarketing surveillance system. Fisher S; Bryant SG; Kluge RM Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073 [No Abstract] [Full Text] [Related]
38. An adverse drug reaction reporting program. Wasan SM; Marshall LB Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356 [No Abstract] [Full Text] [Related]
39. [Proposal of guidelines for the set-up of pharmaco-epidemiologic studies in drug surveillance]. de Tricornot B; Saddier P; Bons B; Clément JP; Courtand M; Lamarque V; Thomas A; Tomczyk S; Vaissère J Therapie; 1997; 52(6):579-85. PubMed ID: 9734111 [TBL] [Abstract][Full Text] [Related]